Prof. Chunrui Li: The Leap from Target Innovation to Clinical Breakthroughs in CAR-T Therapy for Multiple Myeloma

Prof. Chunrui Li: The Leap from Target Innovation to Clinical Breakthroughs in CAR-T Therapy for Multiple Myeloma

To promote innovation in China’s cell and immunotherapy landscape, facilitate in-depth exchange on key scientific questions, share the latest clinical research progress, and strengthen global collaboration and clinical translation, the 2025 International Cell & Immunotherapy Congress (CTI 2025)—jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Society of Immunology, and the Zhejiang Anti-Cancer Association, and co-hosted by the First Affiliated Hospital of Zhejiang University School of Medicine and the Liangzhu Laboratory—was held in Hangzhou from November 13 to 16, 2025.
Professor He Huang: Uniting Global Strength to Lead the Frontier丨2025 International Cell and Immunotherapy Congress

Professor He Huang: Uniting Global Strength to Lead the Frontier丨2025 International Cell and Immunotherapy Congress

To advance innovation in China’s cell therapy and immunotherapy landscape, deepen discussion on key scientific questions, share the latest clinical research progress, and promote global collaboration and clinical translation within the field, the 2025 International Cell and Immunotherapy Congress (CTI 2025) was held in Hangzhou, Zhejiang, from November 13 to 16, 2025. The congress was jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Society for Immunology, and the Zhejiang Anti-Cancer Association, and jointly hosted by the First Affiliated Hospital of Zhejiang University School of Medicine and the Liangzhu Laboratory.
ASH China Voice丨Zunmin Zhu / Mingfeng Zhao / Wenyi Lu: IL-18 and RQR8 Suicide-Switch Dual-Armored CLL-1 CAR-T Cells Enhance the Efficacy and Safety of AML Therapy 

ASH China Voice丨Zunmin Zhu / Mingfeng Zhao / Wenyi Lu: IL-18 and RQR8 Suicide-Switch Dual-Armored CLL-1 CAR-T Cells Enhance the Efficacy and Safety of AML Therapy 

The 67th American Society of Hematology (ASH) Annual Meeting will be held from December 6 to 9, 2025, in Orlando, USA. As one of the largest, most influential, and most comprehensive international congresses in hematology, ASH attracts tens of thousands of experts and scholars from around the world each year to share the latest advances and breakthrough research in the field.
Professor Ye Xiongjun: From Systemic Therapy to Minimally Invasive Surgery — What “Surprises” Await in Kidney Cancer Treatment?

Professor Ye Xiongjun: From Systemic Therapy to Minimally Invasive Surgery — What “Surprises” Await in Kidney Cancer Treatment?

In recent years, the incidence of urological malignancies in China has risen steadily. Prostate, bladder, and kidney cancers now rank among the most common malignancies in the country, posing a serious threat to public health. The Department of Urology at the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS), has long been dedicated to the diagnosis and treatment of urological tumors. With extensive experience in laparoscopic and minimally invasive surgery as well as multidisciplinary cancer management, it stands as a leading force in China’s field of urologic oncology.
Precision Targeted Therapy for Bladder Cancer Reaches a New Milestone: Professor Xu Tao’s Team from Peking University People’s Hospital Demonstrates Potent Synergistic Effects Through Combination Treatment 

Precision Targeted Therapy for Bladder Cancer Reaches a New Milestone: Professor Xu Tao’s Team from Peking University People’s Hospital Demonstrates Potent Synergistic Effects Through Combination Treatment 

Bladder cancer is one of the most common malignant tumors of the genitourinary system. In recent years, the emergence of antibody-drug conjugates (ADCs) has brought new hope for patients with advanced bladder cancer. Among them, Enfortumab Vedotin (EV) — an ADC targeting the tumor antigen Nectin-4 — has been hailed as a “precision-guided missile.” However, the molecular mechanisms underlying the variability in EV’s therapeutic response have not been fully elucidated.
NCCU 2025 | Professor Yong Zhang Explains the Advantages, Beneficiaries, and Learning Path of the “Xing’s Neobladder” Technique

NCCU 2025 | Professor Yong Zhang Explains the Advantages, Beneficiaries, and Learning Path of the “Xing’s Neobladder” Technique

Bladder cancer is one of the most common malignancies of the urinary system. Radical cystectomy remains one of the standard treatments, and urinary diversion is a crucial component of this complex procedure.Professor Xing Nianzeng and his team pioneered a novel laparoscopic-friendly orthotopic ileal neobladder reconstruction technique, known as the “Xing’s Neobladder.” This innovative approach utilizes a detubularized ileal segment to construct a spherical, orthotopic ileal neobladder with two peristaltic input loops, preventing urinary reflux and avoiding excessive tension or compression on the left ureter. The design helps preserve upper urinary tract function while ensuring physiological urine flow.During the National Cancer Center Urological Oncology Conference & Medical Frontier Forum (NCCU 2025), Oncology Frontier – Urology Frontier invited Professor  Yong Zhang from the National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, to share his insights on this groundbreaking technique.